Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
Eosinophilia-myalgia syndrome reached epidemic proportions in 1989. Its precise etiology remains uncertain, yet virtually all cases were associated with the ingestion of L-tryptophan containing trace amounts of several chemicals. Clinical and pathologic features of eosinophilia-myalgia syndrome are similar to those of the toxic-oil syndrome, which occurred in Spain in 1981 in association with the ingestion of adulterated rapeseed oil. During the past year, the epidemiology of eosinophilia-myalgia syndrome has been better defined, with a second trace contaminant linked to this condition. Knowledge of the clinical and histopathologic features of eosinophilia-myalgia syndrome has also expanded. These and other important advances in the understanding of eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia are presented.
Silver
R M
RM
Department of Medicine, Medical University of South Carolina, Charleston 29425.
D001937:Brassica; D004802:Eosinophilia / Q000150:complications* / Q000188:drug therapy; D016603:Eosinophilia-Myalgia Syndrome / Q000150:complications / Q000188:drug therapy / Q000209:etiology*; D005208:Fasciitis / Q000150:complications* / Q000188:drug therapy; D005229:Fatty Acids, Monounsaturated; D006801:Humans; D010938:Plant Oils / Q000506:poisoning*; D000074262:Rapeseed Oil
D005229:Fatty Acids, Monounsaturated; D010938:Plant Oils; D000074262:Rapeseed Oil